Aromatase Inhibitor + Growth Hormone Can Optimize Height

Share this content:
Aromatase Inhibitor + Growth Hormone Can Optimize Height
Aromatase Inhibitor + Growth Hormone Can Optimize Height

FRIDAY, Jan. 27, 2017 (HealthDay News) -- Use of an aromatase inhibitor in combination with growth hormone seems effective for optimizing height in 11β-hydroxylase-deficient congenital adrenal hyperplasia (CAH), according to a case report published online Jan. 26 in Pediatrics.

Katherine Hawton, M.B.B.S., from the Bristol Royal Hospital for Children in the United Kingdom, and colleagues describe a 6-year-old patient with CAH who had been suboptimally treated and presented with precocious puberty, hypertension, tall stature, advanced bone age, and a predicted final height of 150 cm.

The researchers confirmed a diagnosis of 11β-hydroxylase deficiency in hormonal profiles and genetic analysis. In an attempt to optimize the patient's growth, he was started on growth hormone and a third-generation aromatase inhibitor, anastrozole, in addition to glucocorticoid replacement. The patient's growth rate improved significantly after initiation of treatment and his bone age advancement slowed. The patient reached a final height of 177.5 cm, which was 11.5 cm above his mid-parental height.

"This patient is only the second reported case of the use of an aromatase inhibitor in combination with growth hormone to optimize height in 11β-hydroxylase-deficient CAH," the authors write. "This novel treatment proved to be highly efficacious, with no adverse effects."

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

FDA OKs Nucala for Eosinophilic Granulomatosis With Polyangiitis

First drug to be approved for rare autoimmune disease that leads to vasculitis

Findings Support Individualized Glycemic Control in T2DM

Findings Support Individualized Glycemic Control in T2DM

Approach saved $13,547/patient vs uniform intensive control, with lower medication costs

Atherosclerosis ID'd in Many Without CV Risk Factors

Atherosclerosis ID'd in Many Without CV Risk Factors

LDL-C independently associated with the presence and extent of atherosclerosis

is free, fast, and customized just for you!

Already a member?

Sign In Now »